Core Points - NRx Pharmaceuticals, Inc. will present at NobleCon21 on December 3rd, 2025, focusing on its expanded initiatives in investigational drugs and therapies for mental health conditions [1][2] - The company has begun generating clinical revenue and has made significant advancements in drug development since its last appearance at NobleCon in 2024 [2] Company Overview - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in Neuroplastic Therapies for central nervous system disorders, including suicidal depression, PTSD, anxiety, and Autism [5] - The company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone), with NRX-100 receiving Fast Track Designation for treating suicidal ideation in depression and NRX-101 receiving Breakthrough Therapy Designation for suicidal bipolar depression [5] - NRx has filed an Abbreviated New Drug Application for its ketamine formulation, anticipating a launch in July 2026 [5] HOPE Therapeutics Overview - HOPE Therapeutics, a subsidiary of NRx, is establishing a network of interventional psychiatry clinics offering various therapies, including ketamine and transcranial magnetic stimulation [6] - The network is the first in Florida to provide the AMPA One Day (ONE-D) treatment, which combines TMS, physician-prescribed D-cycloserine, and lisdexamfetamine for treatment-resistant depression [6] Conference Details - Interested investors can attend the presentation at a discounted rate using a specific discount code [3] - A high-definition video webcast of the presentation will be available on the company's website and other platforms for 90 days following the event [4]

Company Overview - NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system disorders, including suicidal depression, chronic pain, and PTSD [4] - The company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone), with NRX-100 receiving Fast Track Designation for treating suicidal ideation in depression and NRX-101 receiving Breakthrough Therapy Designation for suicidal bipolar depression [4] - NRx Pharmaceuticals has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100, applying for the Commissioner's National Priority Voucher Program for suicidal depression treatment [4] HOPE Therapeutics - HOPE Therapeutics, Inc. is a subsidiary of NRx Pharmaceuticals, aiming to establish a network of interventional psychiatry clinics offering ketamine, transcranial magnetic stimulation (TMS), and other therapies for patients with suicidal depression [5] - The company plans to integrate a digital therapeutic-enabled platform to enhance the clinical benefits of NMDA-targeted drug therapy [5] Upcoming Events - Jonathan Javitt, M.D., M.P.H., Chairman and CEO of NRx Pharmaceuticals, will participate in a fireside chat at H.C. Wainwright's 27th Annual Global Investment Conference on September 8, 2025, from 4:30 to 5:00 PM ET [1] - A webcast of the fireside chat will be available on the company's website, with a replay accessible for 30 days post-event [2] - Management will also engage in one-on-one investor meetings during the conference, with interested investors encouraged to contact their H.C. Wainwright representative or Brian Korb at astr Partners [3]

Core Insights - NRx Pharmaceuticals and its subsidiary HOPE Therapeutics have formed a strategic investor relations partnership with astr partners to enhance their visibility and investor engagement at a critical juncture in their development [1][2][3] Company Overview - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system disorders, including suicidal bipolar depression, chronic pain, and PTSD [4] - The company is advancing NRX-101, which has received FDA designation as an investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression, and plans to file for Accelerated Approval [4] - NRx has filed an Abbreviated New Drug Application (ANDA) for NRX-100, a preservative-free IV ketamine, and is also pursuing a New Drug Application for the treatment of suicidal depression [5] HOPE Therapeutics Overview - HOPE Therapeutics is a wholly-owned subsidiary of NRx Pharmaceuticals, focused on building a network of interventional psychiatry clinics that provide ketamine and transcranial magnetic stimulation (TMS) therapies [6] - The company aims to offer lifesaving therapies for patients with suicidal depression and related disorders, supported by a digital therapeutic-enabled platform [6] Strategic Partnership - The partnership with astr partners is expected to leverage their extensive experience in biotech investor relations and relationships with specialist investors to enhance NRx and HOPE's market presence [2][3] - The investor relations program will include investor targeting, message development, earnings preparation, conference support, and proactive engagement [3]

Core Insights - NRx Pharmaceuticals and its subsidiary HOPE Therapeutics will participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference on June 16-17, 2025 [1][2] - Dr. Jonathan Javitt, CEO of NRx and Co-CEO of HOPE, will present the company's latest advancements, available on demand for registered attendees starting at 7:00 a.m. ET on June 16, 2025 [2][8] - The company will also engage in one-on-one meetings with investors during the conference [2] Company Overview - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system disorders, including suicidal bipolar depression, chronic pain, and PTSD [4] - The company is advancing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain, with plans to file an NDA for Accelerated Approval [4] - NRx has filed an Abbreviated New Drug Application for NRX-100, a preservative-free IV ketamine, and is pursuing a New Drug Application for its use in treating suicidal depression [5] HOPE Therapeutics Overview - HOPE Therapeutics is a subsidiary of NRx Pharmaceuticals, focused on creating a network of interventional psychiatry clinics offering ketamine and other therapies for suicidal depression [6] - The company aims to enhance clinical benefits through a digital therapeutic-enabled platform that complements NMDA-targeted drug therapy [6]

Core Insights - NRx Pharmaceuticals has submitted an Abbreviated New Drug Application (ANDA) for NRX-100, a preservative-free IV ketamine formulation, to the FDA for use in approved indications such as anesthesia and pain management [1][2] Industry Overview - The current annual ketamine market is estimated at $750 million, with projections indicating growth to $3.35 billion globally by 2034 [2][6] - An estimated 5.1 million Americans have received ketamine for medical uses, with demand continuing to rise due to increased clinical focus [2][6] - There is a severe drug shortage of ketamine in the U.S., which is not expected to improve in the near future [6] Company Developments - NRx Pharmaceuticals aims to capture a significant share of the existing ketamine market with its NRX-100 formulation, which eliminates the neurotoxic preservative benzethonium chloride [3][5] - The company plans to file a citizen's petition with the FDA to remove benzethonium chloride from all intravenous ketamine presentations [3][6] - NRx anticipates submitting clinical trial data from over 1,000 patients and real-world data from more than 180,000 patients to support the extension of ketamine's labeled indications to include treatment for suicidal depression [4][8] Regulatory and Patent Status - The FDA has granted a waiver of the $4.3 million NDA fee for NRX-100, recognizing its public health value [5] - NRX-100 has received Fast Track Designation from the FDA, and the company has filed a patent for this novel formulation, seeking protection until 2045 [5][8]

Core Insights - NRx Pharmaceuticals has reported continued momentum into 2025, advancing regulatory filings for NRX-100 and NRX-101, and enhancing its commercial opportunities with new intellectual property protection for NRX-100 [1][5] - The company is focused on expanding its HOPE Therapeutics network of interventional psychiatry clinics, with planned acquisitions aimed at addressing mental health treatment needs [1][14] Key Research and Development and Corporate Activities - NRX-100, a preservative-free IV ketamine for suicidal depression, aims to address a significant public health crisis, with over 13 million adults in the U.S. considering suicide annually [2] - The company has completed stability and sterility assays for NRX-100, demonstrating three years of room temperature shelf stability, and is on track for a New Drug Application (NDA) submission in Q2 2025 [3] - An Abbreviated New Drug Application (aNDA) for existing ketamine indications is planned for Q2 2025, based on the belief that preservative-free formulations will be preferred [4] - The FDA has waived the $4.3 million NDA submission fee for NRX-100, recognizing its public health benefits and small business status [5] - NRX-101, an oral treatment for suicidal bipolar depression, is progressing towards NDA submission with anticipated PDUFA dates in 2025, supported by strong clinical trial data [12][13] Financial Overview - For Q1 2025, the company reported a net loss of $5.5 million, an improvement from a net loss of $6.5 million in Q1 2024, with operational losses also reduced [21] - As of March 31, 2025, NRx Pharmaceuticals had approximately $5.5 million in cash and cash equivalents, with ongoing financing discussions expected to support operations through the end of 2025 [22] HOPE Therapeutics Expansion - HOPE Therapeutics is developing a national network of clinics focused on neuroplastic therapies for treating depression and related conditions, with initial acquisitions expected to generate approximately $15 million in pro forma revenues [14][16] - The company is negotiating additional clinic acquisitions that could represent around $20 million in potential pro forma revenue [17] - Financing agreements totaling $10.3 million have been signed to support these acquisitions, which are non-dilutive to NRx shareholders [19][20]

Core Insights - HOPE Therapeutics, Inc. has signed a term sheet with Universal Capital, LLC to secure $7.8 million in acquisition capital for expanding its network of interventional psychiatry clinics, aiming for a total of $10.3 million in acquisition capital through additional funding [1][8] Company Overview - HOPE Therapeutics is a subsidiary of NRx Pharmaceuticals, focused on establishing a network of clinics that provide neuroplastic treatments, including ketamine and transcranial magnetic stimulation (TMS), for severe depression and PTSD [2][6] - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders, including NRX-101, which is designated as a Breakthrough Therapy by the FDA for suicidal treatment-resistant bipolar depression [7][9] Industry Context - Neuroplastic treatments are gaining recognition for their effectiveness in treating severe depression and PTSD, with clinical trials demonstrating their ability to foster new synaptic connections in the brain [2][3] - The U.S. Department of Veterans Affairs has highlighted the importance of psychedelic treatments, such as ketamine, in addressing veteran suicide, indicating a growing acceptance of these therapies in mainstream mental health care [3][4] Financial Strategy - The funding from Universal Capital is part of a broader strategy to acquire best-in-class clinics, with plans for future funding as additional assets are identified [4][8] - The company aims to address the mental health crisis in the U.S., where over 13 million Americans plan to commit suicide each year, emphasizing the urgent need for effective treatment options [4]

Core Insights - HOPE Therapeutics, Inc. has signed a definitive agreement to acquire Kadima Neuropsychiatry Institute, which will serve as a clinical model for HOPE's treatment offerings and continue its role in neuroplastic therapy research [1][4][6] - Kadima is recognized as a leading interventional psychiatry clinic in California, known for pioneering ketamine treatment for CNS disorders and is profitable with expected growth [2][6] - Dr. David Feifel, a prominent figure in interventional psychiatry, will join HOPE as Chief Medical Innovation Officer, enhancing the company's leadership in mental healthcare [3][6] Company Overview - NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for CNS disorders, including suicidal bipolar depression and PTSD, with its investigational drug NRX-101 designated as a Breakthrough Therapy by the FDA [5][6] - HOPE Therapeutics aims to build a network of interventional psychiatry clinics offering treatments such as ketamine and TMS, supported by a digital therapeutic platform [8] Strategic Implications - The acquisition of Kadima is expected to be accretive to revenue and EBITDA for both NRx and HOPE, indicating a positive financial outlook post-acquisition [6] - The integration of Kadima's expertise and clinical model is aligned with HOPE's strategy to redefine mental healthcare access and delivery [4][6]

Core Viewpoint - HOPE Therapeutics, Inc. is hosting an investor event to discuss strategic initiatives and progress in their clinical pipeline, emphasizing their commitment to mental health innovation [1][2][4]. Company Overview - HOPE Therapeutics is a subsidiary of NRx Pharmaceuticals, focusing on building a network of interventional psychiatry clinics to provide innovative treatments for suicidal depression and related disorders [7]. - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders, including suicidal bipolar depression and chronic pain [5]. Strategic Initiatives - The investor event will cover expansion plans for HOPE's network of clinics and updates on NRx's clinical pipeline [2][4]. - Recent acquisitions of HOPE clinics are aimed at scaling the interventional psychiatry network [8]. Clinical Developments - NRx is preparing to file a New Drug Application (NDA) for NRX-100 (IV ketamine) for treating suicidal depression, following a $4.3 million filing fee waiver from the FDA [6][8]. - NRX-101 has received Breakthrough Therapy Designation and is set for an NDA filing for Accelerated Approval in patients with bipolar depression and suicidality or akathisia [5][8]. Technological Integration - Plans include integrating digital health solutions, such as CRM-based technology and telepsychiatry, to enhance clinical operations across the HOPE network [8].

Core Viewpoint - NRx Pharmaceuticals has filed a patent application for NRX-100, a preservative-free intravenous ketamine formulation aimed at treating suicidal depression, which could provide exclusivity until 2045 if granted [1][2][8] Group 1: Product Development - NRX-100 is specifically designed without benzethonium chloride or other preservatives, addressing safety concerns associated with these compounds [2][8] - The formulation demonstrates room temperature shelf stability without toxic excipients, potentially allowing it to be listed in the FDA Orange Book [2][8] - The company has initiated a New Drug Application (NDA) filing for NRX-100 based on clinical trial results and data from French health authorities [5] Group 2: Regulatory and Market Strategy - NRx Pharmaceuticals has received Fast Track Designation from the FDA for NRX-100, facilitating its development for patients with acute suicidality [5] - The company is committed to delivering safer treatments for suicidal depression, reflecting a focus on patient well-being [3] - The recent FDA fee waiver is expected to aid in the timely completion of the NDA submission [3] Group 3: Company Overview - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system disorders, including suicidal bipolar depression and chronic pain [4] - The company is also developing NRX-101, which has been designated as an investigational Breakthrough Therapy by the FDA [4]